Skip to content
10-K

Annual Report

Vincerx Pharma, Inc.

0001193125-25-065487

← back to feed
Filed
Mar 27, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 21, 2025 5.23M sh
Shares Diluted FY 2024 · Dec 31, 2024 1.9K sh
Shares Diluted restated FY 2024 · Dec 31, 2023 1.07K sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$26.13M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$40.45M
Cash And Equivalents FY 2024 · Dec 31, 2024 $4.99M
Cash And Equivalents FY 2024 · Dec 31, 2023 $12.78M
Stockholders Equity FY 2024 · Dec 31, 2024 $2.72M
Stockholders Equity FY 2024 · Dec 31, 2023 $11.22M
Stockholders Equity FY 2024 · Dec 31, 2022 $47.67M
Current Liabilities FY 2024 · Dec 31, 2024 $5.28M
Current Liabilities FY 2024 · Dec 31, 2023 $5.61M
Total Liabilities FY 2024 · Dec 31, 2024 $5.28M
Total Liabilities FY 2024 · Dec 31, 2023 $7M
Current Assets FY 2024 · Dec 31, 2024 $6.41M
Current Assets FY 2024 · Dec 31, 2023 $14.73M
Total Assets FY 2024 · Dec 31, 2024 $8.01M
Total Assets FY 2024 · Dec 31, 2023 $18.22M
Eps Diluted FY 2024 · Dec 31, 2024 −$15.85
Eps Diluted FY 2024 · Sep 30, 2024 −$15.85
Eps Diluted restated FY 2024 · Dec 31, 2023 −$37.72
Eps Diluted FY 2024 · Sep 30, 2023 −$37.72
Eps Basic FY 2024 · Dec 31, 2024 −$15.85
Eps Basic restated FY 2024 · Dec 31, 2023 −$37.72
Sga Expense FY 2024 · Dec 31, 2024 $15.98M
Sga Expense FY 2024 · Dec 31, 2023 $13.64M
Net Income FY 2024 · Dec 31, 2024 −$30.07M
Net Income FY 2024 · Dec 31, 2023 −$40.16M
Operating Income FY 2024 · Dec 31, 2024 −$31.46M
Operating Income FY 2024 · Dec 31, 2023 −$42.61M